Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Inv. presentation

Y-mAbs Therapeutics, Inc. (YMAB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Investor Contact:"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/09/2023 4 Hamill Laura (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 2,330 shares @ $0
Granted 13,950 options to buy @ $8.13, valued at $113.4k
06/09/2023 4 Wedell-Wedellsborg Johan (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 2,330 shares @ $0
Granted 13,950 options to buy @ $8.13, valued at $113.4k
06/09/2023 4 Ber Gerard (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 2,330 shares @ $0
Granted 13,950 options to buy @ $8.13, valued at $113.4k
06/09/2023 4 GILL DAVID N (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 2,330 shares @ $0
Granted 13,950 options to buy @ $8.13, valued at $113.4k
06/09/2023 4 HEALY JAMES (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 2,330 shares @ $0
Granted 13,950 options to buy @ $8.13, valued at $113.4k
06/09/2023 4 TYAGI ASHU (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 2,330 shares @ $0
Granted 13,950 options to buy @ $8.13, valued at $113.4k
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/26/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "VP, Head of Investor Relations",
"VP, Head of Investor Relations"
05/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "230 Park Avenue, Suite 3350"
05/17/2023 4 Wedell-Wedellsborg Johan (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Bought 101,740 shares @ $9.6462, valued at $981.4k
05/17/2023 4 WG Biotech ApS (Director) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Bought 101,740 shares @ $9.6462, valued at $981.4k
05/08/2023 8-K Quarterly results
Docs: "Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets"
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 8-K Quarterly results
04/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "230 Park Avenue, Suite 3350"
04/03/2023 SC 13G ACORN BIOVENTURES, L.P. reports a 5.3% stake in Y-mAbs Therapeutics, Inc.
03/13/2023 8-K Other Events  Interactive Data
02/14/2023 SC 13G/A HBM Healthcare Investments Ltd. reports a 8.7% stake in Y-mAbs Therapeutics, Inc.
02/14/2023 SC 13G WG Biotech ApS reports a 9.8% stake in Y-mAbs Therapeutics, Inc.
02/09/2023 SC 13G VANGUARD GROUP INC reports a 5.2% stake in Y-mAbs Therapeutics Inc.
02/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "230 Park Avenue, Suite 3350"
02/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/30/2023 4 Lisby Steen (SVP & CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 32,000 options to buy @ $4.55, valued at $145.6k
01/30/2023 4 Lund-Hansen Torben (SVP & CHIEF TECHNICAL OFFICER) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 32,000 options to buy @ $4.55, valued at $145.6k
01/30/2023 4 Rajah Vignesh (SVP & CHIEF MEDICAL OFFICER) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 32,000 options to buy @ $4.55, valued at $145.6k
01/30/2023 4 Smith Susan Laura (SVP & CHIEF COMMERCIAL OFFICER) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 32,000 options to buy @ $4.55, valued at $145.6k
01/30/2023 4 Wilms Joris (SVP & COO) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 32,000 options to buy @ $4.55, valued at $145.6k
01/19/2023 4 Rajah Vignesh (SVP & CHIEF MEDICAL OFFICER) has filed a Form 4 on Y-mAbs Therapeutics, Inc.
Txns: Granted 17,800 shares @ $0
Granted 35,700 options to buy @ $4.7, valued at $167.8k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy